2025年2月到2026年2月，A股市场迎来了一轮强劲的上涨行情。 上证指数从3200点左右起步，一路攀升至4000点上方，累计涨幅达到25.58%。 深证成指的 表现更加抢眼，从11000点附近涨到15000点以上，涨幅高达38.84%。 创业板指更是从2200点飙升至3500点，涨幅接近59%。 科创50指数也不甘示弱，涨幅超过64%。 全市场5484只股票中，有4788只实现了上涨，上涨比例超过87%。 其中869只股票价格翻倍，更有100多只股票涨幅在2倍到20倍之间。 投资者们沉浸在赚钱的喜悦中，社交媒体上到处是晒收益的截图，券商营业部里开户排队的人群络绎不绝。 就在这一片欢腾的市场氛围中，却有700多只股票逆市下跌。 其中跌幅最大的10只股票，股价几乎全部腰斩，跌幅最小的也有42%。 这些股票所属行业各不 相同，有通信服务、环保设备、生物制品、零售、建筑装饰、食品加工、文化传媒、光伏设备、光学光电子等多个领域。 华星创业的股价从年内高点15.88元一路下跌到6.18元，区间跌幅达到63%。 这家通信服务行业的公司，曾经在2023年初达到20.95元的高点，如今股价已经跌回到三年前的水平。 公司20 ...

2月12日，第四十次"滨州企业日"活动在滨州举行。市委书记宋永祥出席活动并讲话，市委副书记、市长李春田主持，市人大常委会主任马俊昀、市政协 主席范连生、市委副书记刘忠远出席。宋永祥代表市四大班子向广大企业家致以亲切慰问，对其为滨州经济社会发展作出的突出贡献表示感谢，肯定过去 一年企业家助力滨州综合实力迈上新台阶的积极作用。他希望全市企业家新的一年落实党中央决策部署和省委工作要求，在"创新之路、开放之路、文明 之路"上持续奋进，争做创新发展的探索者、组织者、引领者；积极融入新发展格局，用好国内国际两个市场、两种资源，走出滨州、走遍全国、走向世 界，演绎更多"滨企创世界"的精彩故事；以党建统领企业文明创建，将文明理念融入生产经营管理，履行好经济、法律、社会和道德责任，推动企业文明 建设提质增效。 ▲市委政法委部署深化助力"滨企创世界"行动相关工作 "滨企创世界"行动开展以来，各级各部门"干字当头、奋发有为"，为企业"出海"积极搭平台、办实事、解难题，在全市营造了"走在前、挑大梁、勇争 先"的浓厚工作氛围。市外办特开通《"滨企创世界"行动工作动态》专刊，对各部门单位"滨企创世界"亮点工作、经验做法进行梳理汇总并刊发 ...

Group 1 - The company plans to advance the Phase III clinical trial of its liquid nasal spray influenza vaccine for the age group of 18-59 in 2026 [1] - The company aims to accelerate the development of its HSV-2 mRNA vaccine to strengthen its mRNA technology platform [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

Core Insights - The chairman of Jilin Tianzheng Biotechnology Co., Ltd., Cai Tiyuan, was awarded the title of Outstanding Private Entrepreneur in Jilin Province for his significant contributions in industrial development, technological innovation, and social responsibility [1][4]. Company Overview - Jilin Tianzheng Biotechnology was established in 2008 and has grown from Jiaohe into a comprehensive enterprise involved in the research, production, and sales of gelatin and its derivatives [1]. - The company has a registered capital of 113 million yuan and total assets of 450 million yuan, with an annual production capacity of 10,000 tons of bone gelatin, 3,000 tons of collagen peptides, and 35,000 tons of calcium hydrogen phosphate [1]. - The company's products are distributed nationwide and exported abroad, achieving a domestic market share of 12.02% [1]. Management Philosophy - Cai Tiyuan adheres to the management philosophy of "doing things based on one's duties and relying on abilities," which has guided the company's operations [4]. - Under his leadership, the company has been recognized as one of the top 100 private enterprises in Jilin Province and has received accolades for quality and integrity in business practices [4]. Community Engagement - As a representative in the Jilin City People's Congress, Cai Tiyuan has built a bridge between government and enterprises, actively promoting rural revitalization through industry chain integration [5]. - He has also been appointed as the honorary president of the Jiaohe Youth Entrepreneurs Association, supporting youth entrepreneurship and embodying the entrepreneurial spirit of responsibility [5].

Core Viewpoint - Changchun Gaoxin responded to investor inquiries regarding management expenses, emphasizing the inclusion of employee compensation, depreciation, and office expenses, and stated that detailed information is available in the regular reports [1] Group 1 - The company is committed to establishing and improving expense control, decision-making mechanisms, and internal control systems [1] - The company aims to ensure the compliant use of funds [1]

格隆汇2月13日丨三诺生物(300298.SZ)公布，公司实际回购时间区间为2025年4月7日至2026年2月12 日。截至本公告披露日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份1575.5 万股，占公司总股本的比例为2.81%，本次回购股份的最高成交价为21.39元/股，最低成交价为17.27元/ 股，成交总金额为3亿元（不含交易费用）。公司本次回购股份资金总额已超过本次回购方案中回购股 份资金总额下限，且不超过回购股份资金总额上限，符合公司既定的回购方案及相关法律法规的要求。 本次回购股份方案已实施完毕。 ...

Core Viewpoint - Chengda Biotech's subsidiary has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine aimed at preventing influenza in individuals aged 60 and above [1] Group 1: Company Developments - Chengda Biotech's subsidiary, Chengda Biotech (Benxi) Co., Ltd., has been granted a Clinical Trial Approval Notice for a high-dose influenza vaccine [1] - The vaccine is classified as a Class 3.2 biological product for preventive use, specifically targeting the elderly population [1] Group 2: Market Potential - The effective component of the vaccine is four times the dosage of the standard influenza vaccine, indicating a potentially higher efficacy [1] - The vaccine has already been approved for market use in several countries and regions, suggesting a strong market demand [1]

经济观察网特宝生物近期公告显示，公司拟发行可转换公司债券募集资金总额不超过15.33亿元，用于 新药研发等项目。同时，公司2025年业绩快报显示营业收入36.96亿元，同比增长31.18%，归母净利润 10.38亿元，同比增长25.39%。 定增股票 业绩经营情况 公司于2026年2月10日晚间披露了2025年业绩快报，显示营业收入36.96亿元，同比增长31.18%，归母净 利润10.38亿元，同比增长25.39%。业绩增长主要受重点产品派格宾销售收入稳定增长及新产品益佩生 上市推动。 以上内容基于公开资料整理，不构成投资建议。 特宝生物于2026年1月26日晚间公告，拟发行可转换公司债券募集资金总额不超过15.33亿元，用于新药 研发项目、生物技术创新融合中心建设项目及创新药物生产改扩项目。这一计划旨在加码主业，提升研 发能力和产能。 ...

针对上述提问，瑞普生物回应称："投资者您好！生物制品13%税率一般计税政策不影响2025年经营成 果；2026年实施后短期实际税负将有所上升。公司产品线齐全，产业链完善，通过优化产品定价与结 构，优化供应商与采购管理，降低税率调整带来的影响。公司严格依规纳税，扎实做好经营管理，为公 司及股东创造价值。相关情况请以公司定期报告披露为准。感谢您的理解与支持！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向瑞普生物提问："生物制品2026年1月1日由3%税额改为13%，对公司盈利水平影 响有多大？" 来源：市场资讯 ...